Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
A review of the clinical pharmacology of methamphetamine
Addiction, 06/29/09
Cruickshank CC et al. - Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance.
Methods- Relevant literature was identified through a PubMed search.
- Additional literature was obtained from relevant books and monographs.
- The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics.
- Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination.
- At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis.
- Its hypertensive effect can produce a number of acute and chronic cardiovascular complications.
- Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Mental Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
Today in Substance Abuse...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Adverse health effects of non-medical cannabis use
The Lancet, 10/19/09
C-reactive protein as a predictor of disease in smokers and former smokers: a review
International Journal of Clinical Practice, 10/12/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


